Table 1:
Sample demographic and clinical characteristics for 53 participants with usable MRI data. All values are report as mean ± SD (min – max). Numbers in brackets [] indicate the number of missing or unusable responses.
| Variable | Descriptive statistics |
|---|---|
|
| |
| Age | 16.25 ± 1.32 (13.67 – 18.39) |
| Sex (M/F) | 18/35 |
| SIQ score | 24.91 ± 18.06 (3 – 76) |
| IAT score | −0.13 ± 0.25 (−1 – 0.32) [1] |
| CDRS-R | 47.89 ± 12 (26 – 81) |
| Tanner | 4.50 ± 0.51(3 – 5) [8] |
| L caudate GMV (mm3) | 3687.28 ± 391.98 (3027.6 – 4899.1) |
| R caudate GMV (mm3) | 3807.74 ± 402.46 (3124.2 – 4718.7) |
| L putamen GMV (mm3) | 5026.90 ± 491.32 (3927 – 6155.5) |
| R putamen GMV (mm3) | 5125.27 ± 485.77 (3874.5 – 6172.2) |
| L NAcc GMV (mm3) | 520.08 ± 95.29 (310.5 – 694.3) |
| R NAcc GMV (mm3) | 555.42 ± 79.11 (390.6 – 714) |
| ICV (mm3) | 1.53 × 106 ± 1.71 × 105 (1.18 × 106 – 1.86 × 106) |
| Medication (psychotropic) (%) | 47.17% |
| Antidepressant | 33.96% |
| Stimulant | 11.32% |
| Benzodiazepine | 3.77% |
| Antipsychotic | 5.66% |
| Other1 | 15.09% |
| Concurrent Therapy | 26.42% |
| No response | 9.43% |
| Therapy2 (%) | 49.06% |
| Age of depressive episode onset | 13.73 ± 2.31 (4 – 17) |
| Age of first SI | 13.17 ± 1.93 (8 – 17) [1] |
| Suicide Attempt (%) | 22.64% |
| Age of first attempt | 13.33 ± 2.39 (10 – 17) |
| Number of attempts3 | 2 ± 1.21 (1 – 5) |
| Handedness (% R dominant) | 96.23% |
| Ethnicity | |
| Hispanic or Latino | 16.98% |
| Not Hispanic or Latino | 83.02% |
| Race | |
| White/Caucasian | 47.17% |
| African American or Black | 3.77% |
| Asian | 18.87% |
| American Indian or Alaska Native | 3.77% |
| Native Hawaiian or Other Pacific Islander | 0% |
| Multiracial | 20.75% |
| Other | 5.66% |
| Parental Level of Education | |
| No GED/no high school diploma | 0% |
| GED/high school diploma | 1.89% |
| Some college, no degree | 9.43% |
| Associate’s degree | 3.77% |
| Bachelor’s degree | 26.42% |
| Master’s degree | 33.96% |
| Doctoral or Professional degree | 15.09% |
| No response | 9.43% |
1
Other medications taken by participants, with () indicating the number of participants on that medication, that did not fit into the above classifications include Gabapentin (1), Trazodone (4), Buspar (1), Dextromethorphan (1), and Cannabidiol (1).
2
Therapy indicates the percentage of participants who reported attending therapy sessions for their depression in the 2 months prior to their first visit.
3
Computed only in participants who reported a history of attempt based on the C-SSRS